STIMULUS Research Group, Vrije Universiteit Brussel, Jette, Belgium; Cluster Neurosciences, Center for Neurosciences (C4N), Vrije Universiteit Brussel, Brussels, Belgium.
STIMULUS Research Group, Vrije Universiteit Brussel, Jette, Belgium; Cluster Neurosciences, Center for Neurosciences (C4N), Vrije Universiteit Brussel, Brussels, Belgium; Pain in Motion Research Group (PAIN), Department of Physiotherapy, Human Physiology and Anatomy, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Jette, Belgium; Department of Neurosurgery, Universitair Ziekenhuis Brussel, Jette, Belgium; Florida Atlantic University, Boca Raton, FL, USA; Research Foundation Flanders (FWO), Brussels, Belgium.
Br J Anaesth. 2024 Nov;133(5):998-1020. doi: 10.1016/j.bja.2024.07.025. Epub 2024 Oct 2.
This systematic review and meta-analysis aimed to inventory all outcome measures that are affected by tapering in chronic noncancer pain and to investigate the effectiveness of tapering.
A literature search was conducted from inception to April 2024 in MEDLINE via PubMed, Web of Science, SCOPUS, EMBASE, and PsycINFO.
The initial database search identified 3969 articles, which were screened by two independent reviewers. Studies evaluating pain medication tapering in adults with chronic noncancer pain were eligible for inclusion. In total, 57 and 34 articles were included in the systematic review and meta-analysis, respectively. Risk of bias assessment demonstrated poor, fair, and good quality in 30, 24, and three studies, respectively. Pain intensity was the most reported outcome measure, as reported in 28 studies. Furthermore, a random-effect three-level meta-analysis was performed. An overall effect size of 0.917 (95% confidence interval 0.61-1.22; P<0.001) was found, indicating a beneficial effect of tapering. In addition, a statistically significant improvement was demonstrated after tapering for pain intensity, headache disability, the number of headache days per month, anxiety, depression, the number of pills consumed per month, the number of days with medication intake per month, pain catastrophising, and pain interference. No statistically significant effect was observed for physical functioning, mental health-related quality of life, opioid use, pain self-efficacy, and physical health-related quality of life.
This systematic review revealed a broad range of outcome measures affected by tapering. Owing to the high risk of bias of the included articles, the results of this meta-analysis must be interpreted with caution.
CRD42023416343 (PROSPERO).
本系统评价和荟萃分析旨在列出受慢性非癌痛减量影响的所有结局指标,并研究减量的效果。
从建库至 2024 年 4 月,通过 PubMed 中的 MEDLINE、Web of Science、SCOPUS、EMBASE 和 PsycINFO 进行文献检索。
最初的数据库搜索确定了 3969 篇文章,由两名独立评审员进行筛选。纳入评估慢性非癌痛成人疼痛药物减量的研究。共有 57 篇和 34 篇文章分别纳入系统评价和荟萃分析。风险偏倚评估显示,分别有 30、24 和 3 项研究质量为差、中、好。疼痛强度是报告最多的结局指标,有 28 项研究报告了该指标。此外,还进行了随机效应三级荟萃分析。总体效应量为 0.917(95%置信区间 0.61-1.22;P<0.001),表明减量有有益效果。此外,在减量后疼痛强度、头痛残疾、每月头痛天数、焦虑、抑郁、每月消耗的药丸数、每月服药天数、疼痛灾难化和疼痛干扰均有统计学显著改善。但物理功能、心理健康相关生活质量、阿片类药物使用、疼痛自我效能和身体健康相关生活质量无统计学显著影响。
本系统评价揭示了受减量影响的广泛结局指标。由于纳入文章的高偏倚风险,必须谨慎解释本荟萃分析的结果。
CRD42023416343(PROSPERO)。